{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+Breast+Stage+IV&page=4", "query": { "condition": "Carcinoma Breast Stage IV", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 1775, "total_pages": 178, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+Breast+Stage+IV&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+Breast+Stage+IV&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T15:06:14.549Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01149083", "title": "Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Locally Advanced Breast Carcinoma", "Metastatic Breast Carcinoma", "Unresectable Breast Carcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 77, "start_date": "2010-06-30", "completion_date": "2024-09-30", "has_results": true, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-10-10T15:06:14.549Z", "location_count": 22, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01149083" }, { "nct_id": "NCT00060372", "title": "Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Childhood Myelodysplastic Syndromes", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Disseminated Neuroblastoma", "Malignant Neoplasm", "Ovarian Choriocarcinoma", "Ovarian Embryonal Carcinoma", "Ovarian Immature Teratoma", "Ovarian Mature Teratoma", "Ovarian Mixed Germ Cell Tumor", "Ovarian Monodermal and Highly Specialized Teratoma", "Ovarian Polyembryoma", "Ovarian Yolk Sac Tumor", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mantle Cell Lymphoma", "Recurrent Neuroblastoma", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage II Ovarian Epithelial Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Multiple Myeloma", "Stage III Ovarian Epithelial Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Ovarian Epithelial Cancer", "Testicular Choriocarcinoma", "Testicular Choriocarcinoma and Embryonal Carcinoma", "Testicular Choriocarcinoma and Seminoma", "Testicular Choriocarcinoma and Teratoma", "Testicular Choriocarcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma", "Testicular Embryonal Carcinoma and Seminoma", "Testicular Embryonal Carcinoma and Teratoma", "Testicular Embryonal Carcinoma and Teratoma With Seminoma", "Testicular Embryonal Carcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma", "Testicular Teratoma", "Testicular Yolk Sac Tumor", "Testicular Yolk Sac Tumor and Teratoma", "Testicular Yolk Sac Tumor and Teratoma With Seminoma" ], "interventions": [ { "name": "ipilimumab", "type": "DRUG" }, { "name": "therapeutic allogeneic lymphocytes", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-03-27", "last_synced_at": "2026-10-10T15:06:14.549Z", "location_count": 5, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060372" }, { "nct_id": "NCT00077857", "title": "A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "capecitabine (Xeloda®)", "type": "DRUG" }, { "name": "docetaxel (Taxotere®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 470, "start_date": "2003-07", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2013-05-10", "last_synced_at": "2026-10-10T15:06:14.549Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Poway", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077857" }, { "nct_id": "NCT03280303", "title": "Palbociclib in Real World Practice", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Advanced Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "non-interventional", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1285, "start_date": "2017-01-04", "completion_date": "2022-12-22", "has_results": true, "last_update_posted_date": "2024-09-20", "last_synced_at": "2026-10-10T15:06:14.549Z", "location_count": 301, "location_summary": "Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 224 more", "locations": [ { "city": "Alabaster", "state": "Alabama" }, { "city": "Bessemer", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03280303" }, { "nct_id": "NCT00437073", "title": "Brain Metastases In ErbB2-Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "topotecan", "type": "DRUG" }, { "name": "lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2007-05", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2015-10-15", "last_synced_at": "2026-10-10T15:06:14.549Z", "location_count": 13, "location_summary": "Washington D.C., District of Columbia • Indianapolis, Indiana • Sioux City, Iowa + 10 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Sioux City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00437073" }, { "nct_id": "NCT02423902", "title": "A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Ad-RTS-hIL-12", "type": "BIOLOGICAL" }, { "name": "Veledimex", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alaunos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 9, "start_date": "2015-07-18", "completion_date": "2016-07-19", "has_results": true, "last_update_posted_date": "2025-08-28", "last_synced_at": "2026-10-10T15:06:14.549Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02423902" }, { "nct_id": "NCT00429572", "title": "Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Stem Cell Infusion", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 19, "start_date": "1998-01", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2012-08-07", "last_synced_at": "2026-10-10T15:06:14.549Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00429572" }, { "nct_id": "NCT03456973", "title": "Nurse AMIE: A Tablet Based Supportive Care Platform in Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Nurse AMIE", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 7, "start_date": "2017-10-01", "completion_date": "2018-04-18", "has_results": false, "last_update_posted_date": "2019-05-03", "last_synced_at": "2026-10-10T15:06:14.549Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03456973" }, { "nct_id": "NCT06247995", "title": "A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "[68Ga]Ga-NeoB", "type": "DRUG" }, { "name": "[177Lu]Lu-NeoB", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 20, "start_date": "2024-08-14", "completion_date": "2027-04-14", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-10T15:06:14.549Z", "location_count": 5, "location_summary": "Los Angeles, California • Newport Beach, California • Rochester, Minnesota + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06247995" }, { "nct_id": "NCT06084481", "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancers", "Esophageal Squamous Cell Carcinoma", "Triple Negative Breast Cancer", "Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer", "Head and Neck Squamous-Cell Carcinoma", "Platinum Resistant High Grade Epithelial Ovarian Cancer" ], "interventions": [ { "name": "ABBV-400", "type": "DRUG" }, { "name": "Itraconazole (ITZ)", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2023-11-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-10T15:06:14.549Z", "location_count": 20, "location_summary": "Duarte, California • San Francisco, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06084481" } ] }